Sector News

St. Jude Medical Appoints David Dvorak to Its Board of Directors

August 6, 2015
Life sciences
(BUSINESS WIRE) – St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the appointment of David C. Dvorak — President and Chief Executive Officer of Zimmer Biomet — to its Board of Directors, effective August 4, 2015.
 
“We are very pleased to have David Dvorak join the St. Jude Medical Board of Directors”
 
Mr. Dvorak has been President and Chief Executive Officer and a member of the Board of Directors of Zimmer Holdings Inc., a worldwide leader in musculoskeletal health care, for eight years. Mr. Dvorak joined Zimmer Holdings Inc. in December 2001 — shortly following the company’s spin-off from Bristol-Myers Squibb — and has served in many executive roles including Group President of Global Businesses, Chief Legal Officer, Executive Vice President of Corporate Services, Chief Counsel and Secretary, Chief Compliance Officer, and Senior Vice President of Corporate Affairs and General Counsel. He currently serves as a member of the Board of Directors of the Advanced Medical Technology Association (AdvaMed), and previously served as Chairman of the Board of AdvaMed.
 
“We are very pleased to have David Dvorak join the St. Jude Medical Board of Directors,” said St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks. “David is a distinguished leader in the medical technology industry and will offer a broad strategic perspective to our business. We look forward to his future contributions as St. Jude Medical continues to deliver on its innovation-based growth strategy.”
 
Source: St. Jude Medical

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend